查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832137

血管性水腫治療市場（按藥物類別、給藥途徑、疾病類型、最終用戶和分銷管道）—全球預測 2025-2032

Angioedema Treatment Market by Drug Class, Administration Route, Disease Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年血管性水腫治療市場將成長至 203.6 億美元，複合年成長率為 17.77%。

主要市場統計數據
基準年2024年 55億美元
預計2025年 64.7億美元
預測年份：2032年 203.6億美元
複合年成長率（%） 17.77%

對血管性水腫的真實介紹，強調臨床複雜性、不斷發展的診斷和治療勢頭如何改變血管性水腫護理和相關人員的優先事項。

血管性水腫是一種異質性臨床挑戰，其特徵是偶發性組織腫脹、可能危及生命的氣道損害，以及涵蓋遺傳、免疫和特發性途徑的多種誘因。隨著對緩激肽介導途徑機制理解的加深、診斷方法的改進以及以分子標靶干預為重點的治療手段的不斷擴展，當代治療模式正在被重塑。臨床醫師越來越重視治療方法，以減少急診室使用率並提高生活品質。

付款人和醫療保健系統正在調整通訊協定，以平衡急性照護需求、長期管理成本和病患依從性。同時，研究投入正轉向精準治療，根據潛在疾病機制和療效預測因子對患者進行分層。目前，轉化醫學研究的重點是針對遺傳性和後天性血管性水腫的生物標記診斷和新型給藥平台。總體而言，這些力量正在從獨立的挽救療法轉向強調預防、個人化治療方法選擇以及免疫學、過敏和重症監護專家之間的多學科合作的綜合治療途徑。

治療創新、門診護理的擴展和監管演變如何共同重新定義血管性水腫的治療模式和商業性需求

血管性水腫治療領域正在經歷一場變革，這得益於分子標靶治療的進展、門診治療模式的拓展以及監管和支付方預期的不斷變化。針對緩激肽路徑和激肽釋放酶活性的精準藥物正在重新定義臨床終點，相關人員越來越關注降低發病頻率和預防呼吸道損傷，而非僅僅治療急性發作。同時，病患向自我給藥和居家醫療的轉變也改變了產品設計的重點，人們更青睞兼具易用性和強大安全性與穩定性的配方和器械。

法律規範也日趨成熟，以適應新型生物製藥和小分子抑制劑，要求申辦方設計強調患者報告結果和長期安全性的證據包。同時，數位健康工具和遠端監控正在為早期療育和提高依從性創造機會，並促進與專科診所和居家照護提供者更緊密的整合。這些轉變正在創造新的競爭動態，其中，價值的展示、真實世界證據的生成以及相關人員之間的合作將決定哪些產品能夠在不同的護理環境中獲得持續應用。

評估美國關稅主導的血管性水腫藥物供應鏈轉變和採購調整對營運和策略的影響

美國的關稅行動和貿易政策調整可能會對血管性水腫藥物的經濟和物流重大影響，影響其投入成本、進口計畫和供應商選擇。隨著關稅相關成本壓力的增加，製造商和經銷商通常會採取以下應對措施：重新評估籌資策略、加快替代供應商的資格審核或本地化生產流程，以降低跨境關稅的影響。這些供應鏈調整可能導致重新評估庫存緩衝、延長複雜生技藥品的前置作業時間，以及優先考慮可靠性和可預測性的分銷網路轉型。

隨著新的成本和可用性考量被納入採購流程，醫療保健提供者和付款人可能會受到間接影響，促使合約重新談判，並在臨床適用的情況下考慮替代治療層級。製造商可以透過跨地區多元化供應鏈、投資國內灌裝和包裝能力以及提高與貿易夥伴的透明度以預測政策變化來緩解關稅相關的中斷。此外，策略性地使用預購承諾和階梯定價，有助於維持弱勢患者群體的可及性，同時在不斷變化的關稅條件下保持商業性可行性。

將治療機制、交付形式、疾病異質性、護理環境和分銷管道與可行的商業化選擇聯繫起來的細分主導洞察

細緻的細分視角揭示如何協調臨床和商業策略，以應對不同的治療層級、給藥偏好、疾病病因、護理環境和通路。根據藥物類別，產品開發人員必須透過將機制特異性結果與以患者為中心的終點和付款人相關指標聯繫起來，來區分緩激肽受體拮抗劑、C1 抑制劑和激肽釋放酶抑制劑的價值主張。這需要產生有針對性的提案，證明每種治療方法在降低發作嚴重程度和改善長期疾病控制方面的比較優勢。根據給藥途徑，市場由注射劑（通常提供快速療效）和口服劑（提供便利性和依從性優勢）之間的實際權衡所驅動。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 北美遺傳性血管性水腫患者採用自行皮下注射 C1 抑制劑治療
  • 針對因子 XII 的新興基因療法在歐洲治療復發性血管性水腫的成本影響分析
  • 患者的偏好正轉向按需使用激肽釋放酶抑制劑，而非預防性 C1 酯酶替代療法
  • 監管途徑和報銷挑戰推遲了兒科友善艾替班特生物相似藥的市場進入
  • 利用電子健康記錄中的真實證據來確定亞洲市場血管性水腫藥物的依從性模式
  • 開發口服生物可利用的緩激肽B2受體拮抗劑以改善慢性血管性水腫的疾病管理
  • 整合遠端醫療平台監測遺傳性和後天性血管性水腫患者的治療結果

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 血管性水腫治療市場（依藥物類別）

  • 緩激肽受體拮抗劑
  • C1抑制劑
  • 激肽釋放酶抑制劑

9. 血管性水腫治療市場（依給藥途徑）

  • 注射
  • 口服

第 10 章血管性水腫治療市場（依疾病類型）

  • 獲得性
  • 遺傳
  • 特發性

第 11 章血管性水腫治療市場（依最終使用者）

  • 居家護理
  • 醫院
  • 專科診所

第 12 章血管性水腫治療市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第13章血管性水腫治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章血管性水腫治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章血管性水腫治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • CSL Behring AG
    • Takeda Pharmaceutical Company Limited
    • BioCryst Pharmaceuticals, Inc.
    • Pharming Group NV
    • Intellia Therapeutics
    • London Allergy Care and Knowledge
    • Sanofi Consumer Healthcare India Limited
    • Intellihealth Solutions Private Limited
    • Evernorth Health, Inc.
    • San Tan Allergy & Asthma
Product Code: MRR-43690106621A

The Angioedema Treatment Market is projected to grow by USD 20.36 billion at a CAGR of 17.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.50 billion
Estimated Year [2025] USD 6.47 billion
Forecast Year [2032] USD 20.36 billion
CAGR (%) 17.77%

An immersive introduction to the clinical complexity, diagnostic evolution, and therapeutic momentum transforming angioedema care and stakeholder priorities

Angioedema presents a heterogeneous clinical challenge characterized by episodic tissue swelling, potentially life-threatening airway compromise, and variable triggers that span genetic, immunologic, and idiopathic pathways. Contemporary care paradigms are being reshaped by a deeper mechanistic understanding of bradykinin-mediated pathways, improved diagnostic algorithms, and an expanding therapeutic armamentarium that emphasizes targeted molecular interventions. Clinicians increasingly prioritize rapid onset of action, durable prophylaxis for high-risk patients, and treatment regimens that support outpatient and home-based administration to reduce emergency utilization and improve quality of life.

Payers and health systems are adapting protocols to balance acute care needs against long-term management costs and patient adherence. Meanwhile, research investments are moving toward precision approaches that seek to stratify patients by underlying disease mechanism and response predictors. Translational efforts now focus on biomarker-driven diagnostics and novel delivery platforms that can address both hereditary and acquired forms of angioedema. Taken together, these forces are driving a transition from episodic rescue therapy toward integrated care pathways that emphasize prophylaxis, personalized treatment selection, and cross-disciplinary coordination among immunology, allergy, and emergency medicine specialists.

How therapeutic innovation, outpatient care expansion, and regulatory evolution are converging to redefine treatment paradigms and commercial imperatives in angioedema

The landscape for angioedema treatment is undergoing transformative shifts driven by advances in molecularly targeted therapies, expanded outpatient care models, and evolving regulatory and payer expectations. Precision therapeutics that target the bradykinin pathway and kallikrein activity are redefining clinical endpoints, with stakeholders increasingly focused on reducing attack frequency and preventing airway compromise rather than merely treating acute episodes. Simultaneously, the move toward self-administration and home-based care is altering product design priorities, favoring formulations and devices that combine ease of use with robust safety and stability profiles.

Regulatory frameworks are also maturing to accommodate novel biologics and small-molecule inhibitors, prompting sponsors to design evidence packages that emphasize patient-reported outcomes and long-term safety. In parallel, digital health tools and remote monitoring are creating opportunities for earlier intervention and improved adherence, enabling tighter integration between specialty clinics and home care providers. These shifts create new competitive dynamics, where value demonstration, real-world evidence generation, and cross-stakeholder alignment will determine which products achieve sustainable uptake across diverse care settings.

Assessing the operational and strategic consequences of tariff-driven supply chain shifts and procurement adaptations for angioedema therapeutics in the United States

Tariff dynamics and trade policy adjustments in the United States can materially influence the economics and logistics of angioedema therapeutics by affecting input costs, import timelines, and supplier selection. When tariff-related cost pressures rise, manufacturers and distributors often respond by reassessing sourcing strategies, accelerating qualification of alternative suppliers, or localizing manufacturing steps to reduce exposure to cross-border duties. These supply chain adaptations can lead to reevaluation of inventory buffers, longer lead times for complex biologics, and shifts in distribution networks that prioritize reliability and predictability.

Healthcare providers and payers may experience indirect effects as procurement processes incorporate new cost and availability considerations, prompting renegotiations of contracts or the exploration of alternative therapeutic classes where clinically appropriate. Manufacturers can mitigate tariff-related disruptions by diversifying supply chains across geographies, investing in onshore fill-finish capabilities, and enhancing transparency with trading partners to anticipate policy shifts. In addition, strategic use of advance purchase commitments and tiered pricing arrangements can preserve access in vulnerable patient populations while maintaining commercial viability under evolving tariff conditions.

Segment-driven insights that connect therapeutic mechanisms, delivery formats, disease heterogeneity, care settings, and distribution channels to pragmatic commercialization choices

A granular segmentation lens reveals how clinical and commercial strategies must align to address distinct therapeutic classes, administration preferences, disease etiologies, care settings, and distribution pathways. Based on drug class, product developers must differentiate value propositions for bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors by linking mechanism-specific outcomes to patient-centric endpoints and payer-relevant measures. This requires targeted evidence generation that speaks to the comparative advantages of each modality in reducing attack severity and improving long-term disease control. Based on administration route, the market is influenced by the practical trade-offs between injectable therapies that often deliver rapid onset and oral agents that offer convenience and adherence benefits; developers must therefore optimize formulation and delivery technology to match intended care settings.

Based on disease type, the needs of patients with acquired, hereditary, and idiopathic forms diverge in diagnostic complexity, genetic counseling requirements, and prophylaxis versus rescue therapy priorities, demanding differentiated clinical pathways and patient education. Based on end user, home care, hospitals, and specialty clinics present unique adoption barriers and training needs, shaping how product support programs and clinical services are structured. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy dynamics influence access, reimbursement pathways, and patient convenience, requiring tailored commercial strategies that account for regulatory, logistical, and payer nuances across each channel.

Regional strategies for aligning regulatory, reimbursement, and access approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize patient reach

Regional dynamics exert a defining influence on development priorities, regulatory alignment, and access pathways for angioedema treatments, requiring differentiated approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, stakeholder emphasis is commonly placed on demonstrating clear clinical value and payer-aligned outcomes to secure formulary placement and outpatient adoption while also supporting home administration programs that reduce acute care burden. Regulatory review processes in this region often encourage robust clinical endpoints and post-approval safety monitoring, shaping evidence strategies that prioritize real-world data collection.

Across Europe, Middle East & Africa, diverse national regulatory regimes and procurement models necessitate flexible market-entry strategies and tailored health-technology assessment dossiers. Manufacturers must be prepared to engage diverse payer panels and adopt adaptive pricing approaches to accommodate public tendering processes and regional reimbursement variability. In the Asia-Pacific region, rapid innovation adoption in some markets is counterbalanced by infrastructure and access disparities in others, creating opportunities for tiered market entry, local partnerships, and capacity-building initiatives that support training for specialty clinics and home-care networks. Across all regions, coordinated regulatory planning and early payer engagement enhance the likelihood of timely access for patients.

How leading developers are pairing mechanism-focused portfolios with delivery innovations, supply-chain partnerships, and patient-centric support to win clinical and commercial adoption

Key company-level behaviors in the angioedema landscape reflect a combination of platform investment, targeted clinical development, and commercial ecosystem building. Leading developers are prioritizing mechanism-specific portfolios while investing in formulation technologies that facilitate self-administration and outpatient use. Strategic alliances with contract manufacturing and logistics providers are increasingly common as firms seek to de-risk supply chains and secure reliable channels for biologic fill-finish and cold-chain distribution.

Commercially, firms are creating integrated patient support services that combine training, adherence tools, and reimbursement navigation to lower barriers to adoption among home care users and specialty clinics. On the evidence front, sponsors are expanding real-world data programs and patient-reported outcome initiatives to supplement pivotal clinical studies and to meet payer expectations for longitudinal effectiveness and safety. Competitive differentiation is emerging through service models as much as product attributes, with successful organizations demonstrating the ability to align clinical benefits with pragmatic delivery and support systems that resonate with clinicians, payers, and patients alike.

Actionable recommendations for executives to align R&D, supply chain resilience, payer engagement, and patient-centric services for sustainable angioedema product adoption

Industry leaders should adopt a multi-dimensional strategy that integrates clinical differentiation, supply resilience, and payer-aligned value demonstration. First, prioritize development programs that clearly link mechanism of action to clinically meaningful endpoints and patient-reported outcomes, ensuring that evidence generation plans address both acute and prophylactic use cases. Second, invest in delivery formats and training programs that enable safe, effective home administration while minimizing the burden on specialty clinics and emergency services. Third, build supply-chain flexibility by qualifying multiple suppliers, exploring local manufacturing partnerships where feasible, and enhancing visibility across distribution layers to preempt disruptions.

Additionally, engage payers early with transparent value dossiers and real-world evidence plans that demonstrate cost-offsets associated with reduced emergency interventions and improved work productivity. Strengthen commercial propositions by aligning distribution strategies with channel-specific access considerations, coordinating with hospital pharmacies, online dispensaries, and retail networks to optimize availability. Finally, develop service-oriented differentiation-patient support, digital adherence tools, and clinician education-to accelerate uptake and sustain long-term adherence across diverse patient cohorts.

A transparent mixed-methods methodology integrating secondary synthesis, targeted stakeholder interviews, and rigorous triangulation to produce decision-focused insights

The research approach combines systematic secondary review, structured primary inquiry, and rigorous triangulation to ensure robust, decision-grade findings. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical practice statements, and publicly available safety and efficacy data to map the clinical landscape and identify mechanistic differentiators. Primary research involved semi-structured interviews with a cross-section of stakeholders, including specialists in immunology and allergy, procurement officials, clinical operations leaders from hospitals and specialty clinics, and patient advocacy representatives to surface adoption barriers and care pathway realities.

Data were triangulated through cross-validation of clinical inputs, supply-chain assessments, and payer perspectives to reconcile divergent viewpoints and highlight consensus-driven implications. Segmentation analysis applied diagnostic, therapeutic, and channel lenses to isolate differential needs across bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors as well as injectable versus oral administration, hereditary versus acquired and idiopathic disease types, and the roles of home care, hospitals, and specialty clinics. Quality control measures included methodological audits, interview verification, and iterative expert review to ensure findings are actionable and replicable.

Concluding synthesis emphasizing the interplay of therapeutic innovation, delivery models, payer engagement, and supply resilience required for meaningful angioedema care advancement

The cumulative analysis underscores a strategic inflection point for angioedema treatment where molecular innovation, delivery optimization, and ecosystem design converge to create new opportunities for improved patient outcomes and differentiated commercial success. Advances in targeted therapeutics and an increased emphasis on home-based care models are shifting clinical practice toward proactive management, while supply chain and policy dynamics require deliberate mitigation strategies to sustain access. Effective commercialization will depend not solely on molecular efficacy but on the ability to demonstrate value to payers, deliver convenient and safe administration options to patients, and ensure distribution reliability across diverse channels.

Looking ahead, organizations that couple robust clinical programs with adaptive supply chains and comprehensive patient support mechanisms will be best positioned to translate scientific progress into meaningful care improvements. Cross-disciplinary collaboration among developers, clinicians, payers, and patient groups will remain essential to align incentives and expedite adoption of therapies that reduce disease burden and enhance long-term quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption rates of self-administered subcutaneous C1 inhibitor therapies among hereditary angioedema patients in North America
  • 5.2. Cost impact analysis of emerging gene therapies targeting factor XII for recurrent angioedema management in Europe
  • 5.3. Patient preference shift towards on-demand kallikrein inhibitors over prophylactic C1 esterase replacement therapies
  • 5.4. Regulatory pathways and reimbursement challenges delaying market access of pediatric-friendly icatibant biosimilars
  • 5.5. Use of real-world evidence from electronic health records to identify angioedema treatment adherence patterns in Asian markets
  • 5.6. Development of orally bioavailable bradykinin B2 receptor antagonists to improve chronic angioedema disease control
  • 5.7. Integration of telemedicine platforms to monitor treatment outcomes in hereditary and acquired angioedema patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Angioedema Treatment Market, by Drug Class

  • 8.1. Bradykinin Receptor Antagonists
  • 8.2. C1 Inhibitors
  • 8.3. Kallikrein Inhibitors

9. Angioedema Treatment Market, by Administration Route

  • 9.1. Injectable
  • 9.2. Oral

10. Angioedema Treatment Market, by Disease Type

  • 10.1. Acquired
  • 10.2. Hereditary
  • 10.3. Idiopathic

11. Angioedema Treatment Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Angioedema Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Angioedema Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Angioedema Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Angioedema Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. CSL Behring AG
    • 16.3.2. Takeda Pharmaceutical Company Limited
    • 16.3.3. BioCryst Pharmaceuticals, Inc.
    • 16.3.4. Pharming Group N.V.
    • 16.3.5. Intellia Therapeutics
    • 16.3.6. London Allergy Care and Knowledge
    • 16.3.7. Sanofi Consumer Healthcare India Limited
    • 16.3.8. Intellihealth Solutions Private Limited
    • 16.3.9. Evernorth Health, Inc.
    • 16.3.10. San Tan Allergy & Asthma

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANGIOEDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 216. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 217. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 241. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 252. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 253. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 264. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 265. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 287. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 297. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 307. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 325. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 326. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 327. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD M